findmyKOL
Clinical trialNCT00358501CompletedPhase 3Interventional

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

SponsorJazz PharmaceuticalsEnrollment134Severe Hepatic Veno-Occlusive Disease
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Facility name not stated

    Vancouver, British Columbia, Canada

  • Facility name not stated

    Toronto, Ontario, Canada

  • Facility name not stated

    Montreal, Quebec, Canada

United States
  • Facility name not stated

    Duarte, California, United States

  • Facility name not stated

    Palo Alto, California, United States

  • Facility name not stated

    Denver, Colorado, United States

  • Facility name not stated

    Atlanta, Georgia, United States

  • Facility name not stated

    Chicago, Illinois, United States

  • Facility name not stated

    Maywood, Illinois, United States

  • Facility name not stated

    Indianapolis, Indiana, United States

  • Facility name not stated

    Baltimore, Maryland, United States

  • Facility name not stated

    Boston, Massachusetts, United States

  • Facility name not stated

    Ann Arbor, Michigan, United States

  • Facility name not stated

    Minneapolis, Minnesota, United States

  • Facility name not stated

    Rochester, Minnesota, United States

  • Facility name not stated

    St Louis, Missouri, United States

  • Facility name not stated

    Omaha, Nebraska, United States

  • Facility name not stated

    Hackensack, New Jersey, United States

  • Facility name not stated

    New York, New York, United States

  • Facility name not stated

    Durham, North Carolina, United States

  • Facility name not stated

    Columbus, Ohio, United States

  • Facility name not stated

    Portland, Oregon, United States

  • Facility name not stated

    Philadelphia, Pennsylvania, United States

  • Facility name not stated

    Houston, Texas, United States

  • Facility name not stated

    Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 2006
Primary completion
30 Sept 2008
Completion
31 Mar 2015
Last update posted
30 Jan 2017
Registered enrollment
134
Registry id
NCT00358501

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.